Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 297 of 5804
-
New drug cocktail aims to stop cervical cancer comeback after surgery
Disease control Not yet recruitingThis study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.
Phase: NA • Sponsor: Jin LI • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy aims to control early lung cancer without surgery
Disease control Not yet recruitingThe goal of this Single-arm, Phase II clinical trial is to learn whether ablation or stereotactic radiotherapy combined with furmonertinib can treat early-stage non-small cell lung cancer in patients who are inoperable or refuse surgery. The main purposes of this study is to ans…
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could engineered immune cells free diabetics from insulin shots?
Disease control Recruiting nowType 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and lifelong dependence on exogenous insulin. The disease results from loss of immune tolerance, with a…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo therapy offers hope for patients with inoperable liver cancer
Disease control Recruiting nowThis study is a single-arm prospective clinical trial that enrolled 94 patients with unresectable hepatocellular carcinoma(HCC) who received first-line treatment with tislelizumab combined with Huaier granule. By comparing the objective response rate (ORR) and other data with tho…
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Ready-Made immune cells take on blood cancers in early trial
Disease control Not yet recruitingPhase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Phase: PHASE1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Light therapy combo targets deadly bile duct cancer in new trial
Disease control Recruiting nowStudy Design: Multicenter, open-label, Single Group Study Population: Patients with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma who are inoperable or unwilling to undergo surgery. Primary Research Objective: To preliminarily evaluate the efficacy of …
Phase: PHASE2 • Sponsor: Shanghai Guangsheng Biopharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising combo therapy shows hope for Hard-to-Treat bile duct cancer
Disease control Recruiting nowBiliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis. Surgery is recognized as the only curative treatment for BTC, however, only about 20% BTC patien…
Phase: NA • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New shot takes aim at genetic high cholesterol
Disease control Recruiting nowHeterozygous Familial Hypercholesterolemia (HeFH) is an autosomal dominant disorder characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of atherosclerotic cardiovascular disease (ASCVD). This trial aims to evaluate the SYH2053 Injecti…
Phase: PHASE3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for seniors with aggressive lymphoma: Four-Drug cocktail aims to spare chemo
Disease control Recruiting nowThis is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Steroid shot after stroke may boost recovery, new trial hopes
Disease control Recruiting nowThe purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion pati…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New obesity drug HDM1005 takes on tirzepatide in head-to-head trial
Disease control Recruiting nowThis is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzep…
Phase: PHASE2 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for aggressive lymphoma: targeted combo trial launches
Disease control Not yet recruitingEvaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Massive cancer DNA hunt aims to stop relapse before it starts
Knowledge-focused Recruiting nowThis study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for earl…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
MRI brain scan could prevent unnecessary stroke surgeries
Disease control Recruiting nowNarrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For l…
Phase: NA • Sponsor: Maastricht University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New triple therapy offers hope for hard-to-treat nose and throat cancer
Disease control Not yet recruitingTo explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), and to determine the maximum tolerated dose (MTD) of chidamide, thereb…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cocktail therapy aims to beat back stubborn leukemia
Disease control OngoingThe purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia
Phase: PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to stop breast cancer return in women with gene mutations
Disease control Not yet recruitingThe study is a randomized, open-label, multicenter phase II clinical trial of the efficacy and safety of fluzopanib in the adjuvant treatment of early breast cancer using germline mutations in homologous recombination repair pathway genes. Study design Patients will be randomized…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Mind-Reading device aims to give voice to the voiceless
Disease control Recruiting nowThe Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech…
Phase: NA • Sponsor: Paradromics • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Radiation boosts cancer drug in Tough-to-Treat myeloma
Disease control Recruiting nowTo learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill combo aims to tackle Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThis study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colo…
Phase: PHASE1, PHASE2 • Sponsor: Luye Pharma Group Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC